Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Glaucoma Start-Ups Reach Critical Mass

This article was originally published in Start Up

Executive Summary

Having validated high intraocular pressure as a certain target for intervention, the Ocular Hypertension Treatment Study spurred on a new wave of innovation in medical devices for glaucoma. Numerous start-ups formed five or six years ago are now beginning to run their devices through clinical trials. Indeed, the field seems to have gained a critical mass of attention. Start-Up has identified more than a dozen emerging device companies treating glaucoma, and the disease remains a target for development programs and acquisitions on the pharmaceutical side as well.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts